Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide plus surfactant for respiratory distress syndrome
IRCT20241116063727N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of budesonide in respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD), sponsored by Hamadan University of Medical Sciences. Started Nov 2024; status: completed.
02
Drugs
budesonide
03
Conditions
respiratory distress syndrome (RDS)bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on IRCT20241116063727N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241116063727N1.